Bio Pharma Dive
APRIL 28, 2022
The regulator has asked Pfizer to closely monitor patients in a hospital setting for a week as part of a deal to end a study suspension that's lasted more than four months.
World of DTC Marketing
APRIL 25, 2022
Gadget firms — starting with Apple and now Fitbit, which Google owns — are selling wearable devices that check heartbeat rhythms and alert users when something is out of sync, according to KHN.com. Although the gadgets are a technical achievement, some cardiologists say the information the devices produce isn’t always helpful. Notifications from the devices aren’t definitive diagnoses.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
APRIL 28, 2022
Women, those who are obese and those on mechanical ventilation are all more likely to suffer from the effects long-term COVID-19
pharmaphorum
APRIL 29, 2022
An artificial intelligence-powered digital tool for diagnosing skin cancers developed by Skin Analytics has been cleared in the UK as a Class IIA medical device, setting up broader use of the technology in patient assessments. DERM is being deployed in pilot studies across five NHS Trusts, for example to see if it can support GPs in referring patients to the urgent two week skin cancer referral laid out in NICE guidelines.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
APRIL 27, 2022
The company is the latest in a growing list of gene therapy developers to restructure and cut jobs during an industry-wide downturn.
BioPharma Reporter
APRIL 26, 2022
Valneva and Pfizer report positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15: and now plan to include this population in an upcoming Phase 3 trial.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
APRIL 25, 2022
An analysis of 10 clinical trials of digital health interventions targeted at patients recently hospitalised for acute heart failure has found they improve outcomes compared to standard care. The meta-analysis by researchers in the US pooled the results of the studies to assess the impact of digital approaches like telemedicine, use of monitoring sensors, Internet-based interventions, smartphone apps, or text messaging/email interactions on all-cause mortality.
Bio Pharma Dive
APRIL 24, 2022
A study testing Alnylam's drug Onpattro in a deadly heart condition was once seen as a sure bet. Now the trial is the source of much debate, and its outcome could influence how future treatments for the disease are developed.
Pharma Mirror
APRIL 24, 2022
Paris, will open in May (18-19) with connectivity, sustainability and user experience identified as the key trends in 2022 influencing innovation across pharmaceutical packaging and drug delivery. The event – which unites major players in pharmaceutical packaging, drug delivery, medical devices and machinery – returns to the Paris Expo, Porte de Versailles (Hall 7.2) and will see 5000 attendees and some 300+ companies exploring next generation technologies and looking ahead to debate the major i
Pharma Times
APRIL 28, 2022
Long-acting hypertension treatment could provide patients with an injection of medication every six months
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
APRIL 27, 2022
As the landscape of healthcare changes, so too must the way that we interpret and measure performance and success. This is particularly evident in marketing. Before the COVID-19 pandemic, measuring engagement typically involved detailed follow-ups, contacting a pool of practitioners to gauge their awareness of a particular product and then extrapolating that information across the country.
Bio Pharma Dive
APRIL 27, 2022
The agency indicated another trial of the drug, developed by Molecular Partners, will be needed. But whether such a study is doable is yet to be determined, according to Novartis' CEO Vas Narasimhan.
Pharma Mirror
APRIL 24, 2022
OSAKA, Japan and TOKYO, Japan. Shionogi & Co., Ltd. and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine. NEC OncoImmunity, an NEC subsidiary that specializes in artificial intelligence-driven biotechnology, is also participating in this research collaboration.
Pharma Times
APRIL 27, 2022
MMM is a global campaign which raises awareness of high blood pressure and its long-term implications
pharmaphorum
APRIL 26, 2022
Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology. The interest in how the human microbiome influences health has grown substantially in the last decade.
Bio Pharma Dive
APRIL 29, 2022
Executives on Friday said that the company's three-drug therapy, a possible threat to Vertex's top-selling medicine Trikafta, didn't meet expectations in a key study. A new combination could start testing next year, however.
Pharma Mirror
APRIL 24, 2022
Barcelona, Spain, April 20, 2022 – Inke, a leading global manufacturer of inhalation APIs wholly owned by Neuraxpharm Group, announces it is investing €9 million to increase production capacity for inhalation APIs. The investment will allow Inke to triple the production capacity of chemical synthesis and the micronisation of inhalation APIs at its manufacturing plant in Castellbisbal, Barcelona, by 2024.
Pharma Times
APRIL 26, 2022
The Foundation also launched a new collaboration with Diabetes UK and the Juvenile Diabetes Research Foundation UK
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
APRIL 29, 2022
AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology drugs and heart failure therapy Farxiga. The new site will be at Kendall Square and will serve as the new corporate headquarters for Alexion – which is currently based across the Charles River in Boston’s Seaport District – as well as housing around 1,500 R&D staff from AZ and Alexion in a new purpo
Bio Pharma Dive
APRIL 28, 2022
Bristol Myers paid $13 billion to acquire the drug's maker, MyoKardia, and expects a top-selling medicine. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant's lofty forecast.
Pharma Mirror
APRIL 24, 2022
Sweden-based NorthX Biologics (“NorthX”), which focuses on process development and large-scale production of advanced biological drugs, has signed a collaboration agreement with Abera Bioscience (“Abera”) for upscaling and GMP manufacturing of its vaccine candidate against pneumococcus, Ab-01.12. NorthX has recently established an innovation hub to offer support to partners in achieving their long-term drug development goals.
Pharma Times
APRIL 25, 2022
Novartis will provide vital volunteering projects, career plans for young people and financial support to local charities
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Scienmag
APRIL 29, 2022
Having understood the ill-effects if sick building syndrome and the need to better conserve energy by incorporating green features, architects are also utilizing certain elements of an architectural design system shown to reduce stress, improve sleep, promote physical and mental health, thereby improving the quality of life for its inhabitants. Credit: Maharishi International University Having […].
Bio Pharma Dive
APRIL 27, 2022
HilleVax and Belite Bio could soon become the first biotechs to go public in almost two months, representing a key test of investors’ willingness to support emerging life sciences companies.
XTalks
APRIL 28, 2022
Los Angeles-based startup PurePlus launched its first consumer brand, Faves, in 2021 as a sustainable alternative to the popular candy brand Startburst. Today, each packet of chewy candy contains one serving of fruits and vegetables and the company works collaboratively with farmers to secure tons of viable produce from ending up in landfills. According to PurePlus, every Faves packet upcycles six carrots, three beets, one sweet potato, half a squash and a quarter of a pumpkin that would have ot
Pharma Times
APRIL 29, 2022
NICE urges older people to stop routine painkiller use – over 10 million in the UK suffer a form of arthritis or other joint conditions
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Scienmag
APRIL 26, 2022
Globally, the prevalence of type 2 diabetes mellitus (T2DM) is increasing. A study publishing April 26th in the open access journal PLOS Medicine by Marisa Miraldo at Imperial College Business School, London, United Kingdom, and colleagues suggests that living near fast food restaurants increases the risk of developing Type 2 diabetes. Credit: Yalinda De Almeida […].
Bio Pharma Dive
APRIL 25, 2022
The results build on early evidence that NK cell treatments may become viable medicines for leukemia and lymphoma, while it's still unclear whether they're as effective, or last as long, as T cell therapies.
pharmaphorum
APRIL 28, 2022
Orders for Merck & Co’s oral antiviral for COVID-19 helped to swell the drugmaker’s first quarter revenues by a massive 50%, although underlying growth was also strong. Lagevrio (molnupiravir) added $3.2 billion to Merck’s top line of $15.9 billion, but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda (pembrolizumab) and the Gardasil human papillomavirus (HPV) vaccine range.
Pharma Times
APRIL 27, 2022
GARDP neonatal sepsis study was carried out in 19 hospitals across four continents
Expert insights. Personalized for you.
325 
Let's personalize your content